Nascent Biotech Receives Full IND Clearance to Begin Phase I Human Trials for Brain Cancer
SAN DIEGO, CA / ACCESSWIRE / December 15, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) On December 7, the Company received a letter from the US Food and Drug Administration (FDA) removing a partial clinical hold on Nascent’s proprietary monoclonal antibody Pritumumab. This allows Nascent to commence Phase I Human Clinical Trials, effective immediately.
Nascent CEO Sean Carrick stated, “The approval by the FDA is a major milestone in Nascent’s efforts to begin Phase 1 clinical trials. With this achievement, Nascent has advanced the asset to begin testing the antibody on humans. Receiving FDA clearance vital first step in the clinical process.
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.